stockrow
Friday 6 November 2026
Export VSEE’s income statement to Excel — free account
VSee Health, Inc.
VSEE Healthcare Health Information Services
VSee Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.6 million, up 40.3% from fiscal 2024.
- Revenue
- −53.9%
- EPS
- +109.9%
- Free cash flow
- −257.6%
- Total debt
- +31.6%
Quarter to June 2026, against a year earlier
1.15
0.00
0.00%
Follow VSEE
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.49 | 0.83 | 0.52 | 0.70 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(5.29) | (4.88) | (3.92) | (13.38) | |
P/B ratio |
0.82 | 1.89 | 1.38 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.52 | 0.79 | 0.21 | 0.71 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.04) | (2.09) | (0.89) | (2.27) | |
EV/FCF |
(1.03) | (2.07) | (0.88) | (2.25) | |
Quick Ratio |
0.33 | 0.34 | 0.45 | 0.13 | |
Current Ratio |
0.40 | 0.41 | 0.52 | 0.16 | |
Net Debt/EBITDA |
(0.16) | 0.24 | 1.28 | (0.08) | |
Debt/Assets |
4.67% | 4.11% | 2.65% | 3.15% | |
Debt/Equity |
0.10 | 0.12 | 0.11 | (0.11) | |
Asset Turnover |
0.72 | 0.75 | 0.69 | 0.66 | |
Operating CF/Net income |
(1.39) | 0.94 | 0.25 | 2.60 | |
Capex/Depreciation |
0.00 | (0.04) | (0.01) | (0.03) | |
Interest Coverage |
(33.42) | (26.30) | (3.75) | (2.72) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
185.90% | 132.03% | 176.92% | 103.77% | |
Intangible Assets out of Total Assets |
0.75 | 0.69 | 0.61 | 0.76 | |
Share Based Compensation of Revenue |
12.97% | 13.96% | 9.18% | 0.00% | |
Graham Net Nets |
(0.95) | (0.66) | (1.14) | (2.04) | |
Graham Number |
0.00 | 0.00 | 0.00 | 162.21 | |
Earnings Yield |
(393.09%) | (216.79%) | (195.10%) | (88.92%) | |
Free Cash Flow Yield |
(102.62%) | (46.07%) | (46.29%) | (44.94%) | |
Revenue per Share |
2.33 | 5.28 | 15.59 | 19.24 | |
Operating CF per Share |
(1.75) | (4.10) | (7.65) | (3.65) | |
Capex per Share |
0.00 | (0.04) | (0.03) | (0.11) | |
Free Cash Flow per Share |
(1.75) | (4.14) | (7.68) | (3.76) | |
Cash per Share |
0.68 | 2.25 | 20.06 | 2.29 | |
Shareholders Equity per Share |
11.32 | 10.56 | 21.65 | (26.95) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.32 | 10.56 | 21.65 | (26.95) | |
Free Cash Flow |
(1.17) | (2.48) | (1.93) | (0.78) | |
Working Capital |
(4.83) | (6.95) | (7.88) | (19.70) | |
Capital Expenditures |
— | (0.03) | (0.01) | (0.02) | |
Net Current Asset Value |
(5.88) | (7.85) | (8.60) | (20.56) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.92 | 2.26 | 1.98 | 2.60 | |
Average Payables |
8.01 | 8.99 | 9.34 | 9.99 | |
Average Assets |
17.47 | 19.21 | 21.20 | 21.87 | |
Average Common Equity |
0.93 | 1.41 | 2.72 | (0.41) |
Columns are period end dates · fundamentals updated 2 Nov 2026